Duke to Participate in Early Clinical Trials for Emerging Neurological Therapies

Contact: Samiha Khanna Phone: 919-419-5069 Email: samiha.khanna@duke.edu https://www.dukehealth.org FOR IMMEDIATE RELEASE on Thursday, July 21, 2016 DURHAM, N.C. -- Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer ’s disease and neuropathy. The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, awarded the 10-year contract to Duke to design, manage, and conduct Phase I clinical trials. The trials will be conducted at the Duke Clinical Research Unit (DCRU), the early-phase clinical trial unit of the Duke Clinical Research Institute. The DCRU ’s state-of-the-art 40-bed study and observation facility is one of a small number of academic early phase research units in the country. Support for the contract will be provided as part of the NIH Blueprint for Neuroscience Research Neurotherapeutics Network. The goal of the network is to speed the transition of promising new therapies from the lab to the clinic by supporting early stages of research and then working with industry to get treatments to patients. “This award reinforces Duke’s position as a leader in early-phase trials,” said Andrew Krystal, M.D., director of the Neurosciences Medicine Research Program at the Duke Clinical Research Institute, who will serve as the principal investigator for the trials. “It’s an opportunity...
Source: DukeHealth.org: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

Abstract As the global population ages, the incidence of neurodegenerative diseases has risen. Furthermore, it has been suggested that depression, especially in elderly people, may also be an indication of latent neurodegeneration. Stroke, Alzheimer's disease (AD), and Parkinson's disease (PD) are usually accompanied by depression. The urgent challenge is further enforced by psychiatric comorbid conditions, particularly the feeling of despair in these patients. Fortunately, as our understanding of the neurobiological substrates of maladies affecting the central nervous system (CNS) has increased, more therapeutic ...
Source: Neural Plasticity - Category: Neurology Authors: Tags: Neural Plast Source Type: research
It would dedicate $1.5 billion of its total to research and therapy for Alzheimer ’s Disease, Parkinson’s Disease, stroke, epilepsy and other brain and central nervous system conditions.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
This report summarizes the discussion and recommendations from a working group convened by the National Heart, Lung, and Blood Institute and the National Institute of Neurological Disorders and Stroke to evaluate the state of the field in VCID research, identify research priorities, and foster collaborations. As discussed in this report, advances in understanding the biological mechanisms of VCID across the wide spectrum of pathologies, chronic systemic comorbidities, and other risk factors may lead to potential prevention and new treatment strategies to decrease the burden of dementia. Better understanding of the social d...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
It would dedicate $1.5 billion of its total to research and therapy for Alzheimer ’s Disease, Parkinson’s Disease, stroke, epilepsy and other brain and central nervous system conditions.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
This study examined the amount of variance in age-related cognitive change that is accounted for by AD and stroke using a novel pattern re cognition protocol.Method: Secondary analyses of data collected for the Health and Retirement Study (N = 17,579) were used to objectively characterize patterns of cognitive decline associated with AD and stroke. The rate of decline in episodic memory and orientation was the outcome of interest, while algorithms indicative of AD and stroke pathology were the predictors of interest.Results: The average age of the sample was 67.54 ± 10.45 years at baseline, and they completed, on av...
Source: Neuroepidemiology - Category: Epidemiology Source Type: research
Abstract Conventionally cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as "cardiac diseases," especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer's disease. Alzheimer's disease is also one of the other CNS conditions where measuring ca...
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Tags: CNS Neurol Disord Drug Targets Source Type: research
ConclusionTSPO was only expressed in the stroke-induced insult and proximal tissue and therefore was unable to detect remote and non-insult-related chronically activated microglia overexpressing MHCII in WM. This suggests that research in neuroinflammation, particularly in the WM, would benefit from MHCII-sensitive radiotracers.
Source: EJNMMI Research - Category: Radiology Source Type: research
ConclusionsCortical MV density and diameter are not appreciably altered by ADNC or CAA. TSG-6 and HA are increased in both ADNC and CAA, with laminin and col IV decreased in the BM of high ADNC, but laminin increased in moderate-severe CAA. These results show that changes in the ECM occur in AD and CAA, but independently of one another, and likely reflect on the regional functioning of the brain microvasculature.
Source: Fluids and Barriers of the CNS - Category: Neuroscience Source Type: research
In conclusion, it remains unclear if brain-specific regional and temporal changes occur in the expression of the different APP variants during AD progression. Since APP is also found in blood cells, assessing the changes in APP mRNA expression in peripheral blood cells from AD patients has been considering an alternative. However, again the quantification of APP mRNA in peripheral blood cells has generated controversial results. Brain APP protein has been analyzed in only a few studies, probably as it is difficult to interpret the complex pattern of APP variants and fragments. We previously characterized the soluabl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
DISCUSSION: Our association of MYH11, FZD3, SORCS3, and GOLGA8B with dementia is supported by independent functional studies in human subjects, model systems, and associations with shared risk factors for stroke and dementia. PMID: 32966694 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
More News: Academia | Alzheimer's | Brain | Clinical Trials | Contracts | Health | National Institutes of Health (NIH) | Neurology | Pediatrics | Stroke | Study